A Phase III Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Efficacy and Safety of TMC207 in Subjects With Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Bedaquiline (Primary)
- Indications Pulmonary tuberculosis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Infectious Diseases BVBA
- 06 Feb 2014 According to the ClinicalTrials.gov record, Status changed from recruiting to withdrawn prior to recruitment.
- 19 Dec 2013 Planned End Date changed from 1 Oct 2020 to 1 Nov 2022 as reported by ClinicalTrials.gov.
- 11 Apr 2013 Planned end date changed from 1 Apr 2018 to 1 Oct 2020 as reported by ClinicalTrials.gov.